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Drug shortages are a national tragedy and represent a true
public health crisis. Drug shortages prevent patients from
accessing lifesaving medications and are directly linked to
medication errors, substantial economic cost, inferior patient
outcomes, and even patient deaths [1]. The recent shortage of
vincristine, a chemotherapeutic used by nearly every child
with cancer and by countless adults, represents what has been
called “a nightmare situation” [2]. There is no substitute or
alternative for vincristine. Confronted with the vincristine
shortage, U.S. oncologists collectively hyperventilated with the
expectation of looking patients in the eye and conveying that
a potentially lifesaving drug is simply unavailable [3].
Vincristine is not expensive—in most of the world, it costs
less than a carton of eggs. It is not new or exotic—isolated dur-
ing the Cold War, it is readily synthesized. And its efficacy is
proven—it is a component of dozens of oncologic regimens. In
fact, vincristine is a World Health Organization (WHO) essential
medicine. So how can the United States simply run out?
Drug shortages represent a symptom of our inherently
damaged health care system. Pharmaceutical companies
are responsible to their shareholders; when products are
not profitable, through the fault of the marketplace, they
are deprioritized. These negative externalities of our cur-
rent governance structure can only be fixed with legislative
sea change. We briefly review how we got here and suggest
how we can move forward.
In February 2018, vincristine, a generic medication for
many Food and Drug Administration (FDA)-approved cancer
indications, became scarce. At the time, vincristine was man-
ufactured by Pfizer and Teva. Patients, clinicians, and hospitals
struggled to cope with this shortage and breathed a collective
sigh of relief once production and supply resumed. With little
warning, in July 2019, Teva made a business decision to dis-
continue production, leaving the United States with only one
producer of this critical medication required by scores of
patients. In October 2019, Pfizer experienced manufacturing
delays and increased demand, resulting in a national vincris-
tine shortage. As a result, hospitals and clinicians (once again)
faced the unenviable task of rationing this lifesaving medica-
tion among equally deserving patients. Although clinicians
and hospitals will invariably make rationing decisions differ-
ently, guidelines for pediatric cancer do exist [4]. These are
based upon a two-step process: step 1 includes strategies to
mitigate an existing shortage based upon maximizing effi-
ciency and minimizing waste while step 2 elucidates actual pri-
oritization grounded upon a modified utilitarian model that
maximizes benefit according to total lives saved/life-years
saved. Although the focus of the guidance is childhood cancer,
the ethical reasoning for explicit decision-making in the face
of an actual drug shortage applies broadly to pediatrics and
adult medicine in general.
There is simply not enough profit in the production of
many cheap, proven, decades-old generic medications like
vincristine. Teva is not nefarious—it is a company that needed
to shave its inventory to stay solvent. As appreciated by count-
less experts, including pharmaceutical insiders, scholars, and
the FDA, economics are the primary driver of U.S. drug short-
ages [1]. The issue involves how drug prices are set and reim-
bursed in our fundamentally broken system. For this reason,
vincristine is only one of hundreds of scarce drugs each year in
this country. Institutions are forced to develop ethically appro-
priate, transparent evidence-guided rationing schema, while
expending extraordinary efforts to conserve and procure sup-
plies of drugs on shortage. Rosovsky et al. provide a detailed
description of their institutional response to the recent hepa-
rin shortage, illustrating the magnitude of deliberation and
person-hours necessary to create system-level changes to pro-
tect patients in the face of a crisis [5]. The role of ethicists in
anticipating and responding to these situations is also critically
important.
Institutions would greatly benefit from improved com-
munication and a coordination strategy with regional and
statewide partners facing similar circumstances—although
Rosovsky’s article is timely and of significant value, we are
sure many hospitals across the country would have appreci-
ated being able to better share information and best prac-
tices in real time. Unfortunately, despite calls for such a
system, currently no structure exists to do so.
We have made some progress. The 2012 FDA Safety and
Innovation Act (FDASIA) requires manufacturers to notify the
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FDA of anticipated supply delays and shortages, avails foreign
drug supplies in certain dire situations, and empowered the
FDA to develop a related strategic plan. Yet, at best, FDASIA
was a band-aid.
Last month, the FDA released a long-anticipated report
that summarized and contextualized the current state of U.S.
drug shortages [1]. Their recommendations included creating
a shared understanding of impact, developing a rating sys-
tem to incentivize consistent production and to encourage
viable contracts with industry. At least some of these pro-
posals are built into the 2020 congressional budget proposal.
Notably, many of these recommendations had previously
been articulated [6].
Although realistic, one cannot but be dismayed by the
concluding statement of the FDA report [1], “…it is likely that
drug shortages will continue to persist absent major changes
to this marketplace.” Herein lies a missed opportunity. A rec-
ommendation for greater direct governmental involvement
could have, and arguably should have, been suggested. As
one of us recently noted, “The government has previously
stepped into the marketplace to assist the ailing automotive
industry, Wall Street, and the insurance companies. Why not
do the same for our ailing health care system, specifically,
the manner in which lifesaving medications are man-
ufactured and distributed?” [7]. The government could
identify a willing and capable partner with whom to ally
to produce affordable and accessible medications reim-
bursed at a fair price. Related, “essential medications must
be viewed as critical infrastructure not unlike public utilities
such as electricity and water” [7]. Doing so is one way to
guarantee continuous production and availability for patients
in need.
Since the 1970s, international guidance on drugs deemed
most critical to maintain has existed. The WHO maintains an
updated list of essential medicines that nations should read-
ily have. The list is thoughtfully curated based upon data-
driven efficacy, relevance, and cost-effectiveness. At the very
least, our federal government can and should incentivize pro-
duction of these drugs and, ideally, in a nation of our wealth
and privilege, expand upon it. Earlier this year, a U.S. list of
essential medicines for childhood cancer, including recom-
mendations for assuring production of these medications,
was proposed [8].
A new European consortium, the International Horizon
Scanning Initiative, provides a compelling paragon [9]. Last
month, Dutch Minister Bruins announced a novel strategic
alignment of nine countries focused on drug pricing, delivery,
and supply. This type of collaboration and communication is
critical to integrating and creating systems that can readily
avail access, and incentivize production for needed drugs,
rather than only those that are currently lucrative. America
sorely needs to take a similarly bold and creative step.
Drug shortages represent a threat to national security. The
U.S. drug supply is overly dependent on foreign powers; nearly
90% of the raw ingredients we rely upon for U.S. drugs come
from China and India, and more than 25% of medications
labeled as “made in America” are actually made abroad in
FDA-inspected plants [10]. This has significant implications
regarding medication quality, safety, and accessibility. We cur-
rently rely on foreign powers to bail us out when our system
cannot take care of our own citizens. America has the capacity
and ability to provide health care not only to its own citizens
but across the world, and it has a proud history of doing just
that. We need to do at least as well for our own people.
Over the past months, there appears to be renewed
interest in addressing U.S. drug shortages. The same day the
FDA report was released, U.S. Senators Collins, of Maine,
and Smith, of Minnesota, introduced a bipartisan bill coined
the Mitigating Emergency Drug Shortages Act, which aimed
to increase accessibility and affordability of vital drugs
required by patients. The U.S. Senate Homeland Security and
Governmental Affairs Committee also produced a report,
“A Price Too High: Cost, Supply, and Security Threats to
Affordable Prescription Drugs,” with tangible and actionable
solutions [11]. Furthermore, on November 13, Teva USA
announced their plan to reintroduce vincristine to the U.S.
market as early in 2020 as possible [12]. We are hopeful that
meaningful strides will come from these and related efforts.
In summary, our country’s perverse drug pricing system
creates drug shortages that threaten the lives of the most vul-
nerable Americans, including children with cancer. We need
federal legislation to ensure that patients in need are able to
access essential medications. International precedents and les-
sons organized by WHO and recently spearheaded in Europe
exist. Americans need and deserve access to lifesaving medica-
tions, which will require lawmakers and regulators to coordi-
nate and act. Patients’ lives depend upon it.
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Editor’s Note:
See the related article, “When Pigs Fly: A Multidisciplinary Approach to Navigating a Critical Heparin Shortage” by
Rachel Rosovsky, Megan Barra, Russel Roberts et al. on page 334 of this issue.
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